Want to join the conversation?
$BIIB said it is preparing to launch Zinbryta in Aug. 2016 in the US and Germany. Zinbryta is the first in a new class of multiple sclerosis therapy. The company added that Zinbryta will be used by patients switching for efficacy reasons, benefiting from once monthly at home subcutaneous administration and a differentiated mechanism of action.
$WBA is yet to receive US anti-trust clearance for its Rite Aid acquisition. The deadline for the deal expires on January 27.
$BMY plunge 7.2%. No credits to the non-acceleration of approval for lung cancer combination treatment.
Well this is big! I don’t know if it’s someone’s monopoly or genuine excitement, but either way, $CSX is up 23% after market closed. I heard some activist investor is going to blow big money into CSX Corp. Anyone mind explaining?